Loading…
Employees: 1,973
Size Genky DrugStores (9267.T) is a Japan Consumer Staples company (Drugstore Chains) with a market value of $723M, the 884th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥3,710 on 6 Nov 2026.
Performance Over six months the shares gained 2.9%, against -2.0% for the median peer and +1.8% for the Japan market (cap-weighted) — 7th highest of 17 in its peer set.
Growth Revenue grew 8.4% over the last twelve months (peer median +5.6%); the operating margin is 4.8% (peer median 4.3%).
Valuation It trades at 13.7× forward earnings against a peer median of 16.3× (5th cheapest of 10).
Capital Return on invested capital runs 2.6 points above its cost of capital (5.8% WACC).
Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | ¥224B | ¥221B | ¥201B | ¥185B | ¥169B |
| Revenue growth | — | +10% | +9% | +9% | — |
| Gross profit | ¥45.7B | ¥38.3B | ¥35.1B | ¥32.5B | ¥29.9B |
| EBITDA | ¥18.2B | ¥18.1B | ¥16.0B | ¥14.6B | ¥11.7B |
| Net income | ¥7.72B | ¥7.88B | ¥7.07B | ¥6.32B | ¥4.76B |
| Free cash flow | n/a | -¥3.13B | -¥2.50B | ¥2.98B | -¥1.12B |
| Capital expenditure | n/a | ¥20.1B | ¥15.1B | ¥10.4B | ¥9.93B |
| Total debt | ¥40.5B | ¥39.6B | ¥34.4B | ¥30.6B | ¥32.4B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 9267.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.7% | +0.8% | 4th highest of 17 |
| 6-month return | +2.9% | -2.0% | 7th highest of 17 |
| Distance from 52-week high | -32.0% | -31.0% | 9th highest of 17 |
| Revenue growth (TTM) | +8.4% | +5.6% | 8th highest of 17 |
| Operating margin | 4.8% | 4.3% | 7th highest of 17 |
| Forward P/E | 13.7× | 16.3× | 5th cheapest of 10 |
| ROIC minus cost of capital | +2.6 pp | +2.7 pp | 8th lowest of 17 |
| EV / EBITDA | 7.7× | 6.4× | 4th most expensive of 8 |
| Net debt / EBITDA | 1.5× | -0.4× | 3rd most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Genky DrugStores 9267.T | Japan | $723M | +3% | +8% | 5% | 13.7× | n/a | n/a |
| MedPlus Health Services MEDPLUS.NS | India | $769M | -31% | +21% | 4% | 35.1× | 18.5% | +17.6% |
| Anhui Huaren Health Pharmaceutical 301408.SZ | China | $829M | -35% | +15% | 8% | n/a | -6.0% | +23.3% |
| Beijing Konruns Pharmaceutical 603590.SS | China | $617M | -28% | +4% | 20% | 21.0× | 11.6% | +2.7% |
| Shu Yu Civilian Pharmacy 301017.SZ | China | $872M | +9% | +9% | 2% | n/a | 4.0% | +17.4% |
| Cawachi 2664.T | Japan | $577M | +37% | -1% | 2% | n/a | -5.8% | 0.0% |
| Qol 3034.T | Japan | $567M | +38% | +7% | 6% | 11.3× | -16.2% | +12.4% |
| Luyan Pharma 002788.SZ | China | $555M | -30% | +3% | 3% | n/a | 0.1% | +6.5% |
| Yixintang Pharmaceutical 002727.SZ | China | $1.18B | +6% | -2% | 3% | 16.9× | -15.9% | +6.5% |
| Ain 9627.T | Japan | $1.23B | -2% | +42% | 4% | 13.4× | -6.5% | +16.9% |
| Create SD 3148.T | Japan | $1.30B | -2% | +9% | 5% | n/a | -11.5% | +8.0% |
| Landfar Bio-medicine 000504.SZ | China | $395M | -16% | +497% | -2% | n/a | n/a | n/a |
| Shanghai No. 1 Pharmacy 600833.SS | China | $314M | -24% | +1% | -1% | n/a | 20.4% | +6.1% |
| LBX Pharmacy Chain Joint Stock 603883.SS | China | $1.69B | +7% | +3% | 5% | 16.3× | -10.9% | +9.7% |
| JZJ Chain Drugstore Corporation 605266.SS | China | $307M | -34% | -5% | 0% | 6.5× | -9.6% | +14.8% |
| Guardian Pharmacy Services GRDN | United States | $2.68B | +17% | +10% | 6% | 30.6× | 4.1% | +16.8% |
| Sundrug 9989.T | Japan | $2.77B | -1% | +4% | 5% | 13.3× | -8.0% | +5.8% |